CCL5 and ductal breast carcinoma in situ: Next, we compared the three groups of breast cancer patients (DCIS, IDC-no-relapse, IDC-with-relapse) with respect to the incidence of expression of CCL2, CCL5, TNFα and IL-1β in the tumor cells.